Table 4

Clinical features of 144 NAFLD patients and 257 healthy controls with very low probability of steatosis from Northern Italy according to thePNPLA3I148M genotype
NAFLD patients (n = 144) p value*
PNPLA3 genotype CC (n = 55) CG (n = 68) GG (n = 21)
Age (years) 49±13 51±12 47±12 0.87
Sex (F) 15 (27) 12 (18) 5 (24) 0.58
BMI (Kg/m2) 26.8±3.7 27.1±3.1 26.0±3.0 0.62
ALT (IU/ml) 54±38 58±49 80±54 0.06
Diabetes 3 (5.5) 11 (16.2) 3 (14.3) 0.13
Insulin (IU/ml) 14.6 {11.7-19.9} 13.4 {10.2-20.2} 16.8 {11.5-22.1} 0.33
Glucose 94±21 101±34 97±16 0.43
HOMA-IR 3.1 {2.5-4.5} 3.3 {2.4-4.5} 3.3 {2.4-5.5} 0.57
FFAs (mmol/l) 0.21±0.09 0.22±0.08 0.22±0.09 0.85
Adipo-IR 14.2±15.1 13.9±13.9 17.9±15.4 0.78
Adiponectin (μg/ml) 5.5 {3.0-9.9} 4.9 {3.0-7.4} 3.8 {2.7-6.5} 0.03
    Controls (n = 257)
p value*
PNPLA3 genotype CC (n = 146) CG (n = 95) GG (n = 16)
Age (years) 46±12 51±12 45±14 0.51
Sex (F) 37 (25) 15 (16) 3 (19) 0.83
BMI (Kg/m2) 24.8±2.7 25.2±2.8 25.2±4.2 0.71
ALT (IU/ml) 21±7 24±8 22±6 0.48
Insulin° (IU/ml) 11.8 {9.5-14.0} 11.9 {9.2-15.4} 9.0 {7.6-14.8} 0.17
Glucose 89±6 89±6 86±3 0.89
HOMA-IR° 2.5 {1.9-3.2} 2.6 {2.0-3.4} 1.8 {1.7-3.0} 0.10
FFAs° (mmol/l) 0.16±0.07 0.14±0.06 0.23±0.02 0.93
Adipo-IR° 6.4±2.8 5.2±2.1 8.1±0.9 0.47
Adiponectin (μg/ml) 7.0 {4.7-9.9} 6.2 {4.7-8.8} 5.6 {4.2-7.4} 0.04

* p for trend across PNPLA3 genotypes, °available in 68 controls. BMI body mass index, IFG impaired fasting glucose, HOMA-IR homeostasis model assessment insulin resistance index, FFAs free fatty acids, Adipo-IR adipose tissue insulin resistance index, ():% values, {}: interquartile range.

Valenti et al.

Valenti et al. BMC Gastroenterology 2012 12:111   doi:10.1186/1471-230X-12-111

Open Data